Puma Biotechnology (PBYI) PT Lowered to $91.00 at JPMorgan Chase & Co.

Puma Biotechnology (NASDAQ:PBYI) had its target price cut by equities research analysts at JPMorgan Chase & Co. from $138.00 to $91.00 in a report issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 32.46% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Leerink Swann increased their price objective on Puma Biotechnology to $140.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Zacks Investment Research downgraded Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, January 15th. Credit Suisse Group set a $142.00 price objective on Puma Biotechnology and gave the company a “buy” rating in a research report on Monday, January 15th. BidaskClub upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 3rd. Finally, Stifel Nicolaus increased their price objective on Puma Biotechnology from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $110.56.

Puma Biotechnology (PBYI) traded up $0.60 on Wednesday, reaching $68.70. The company’s stock had a trading volume of 1,262,627 shares, compared to its average volume of 1,108,942. The firm has a market capitalization of $2,555.76, a P/E ratio of -8.40 and a beta of 0.72. Puma Biotechnology has a 12-month low of $28.35 and a 12-month high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same quarter last year, the company earned ($1.11) earnings per share. analysts forecast that Puma Biotechnology will post -8.16 EPS for the current year.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 1,860 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $92.75, for a total transaction of $172,515.00. Following the transaction, the senior vice president now directly owns 25,379 shares of the company’s stock, valued at $2,353,902.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Charles R. Eyler sold 1,322 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,874 shares of company stock worth $1,303,616. Company insiders own 21.10% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund increased its position in Puma Biotechnology by 4.7% during the second quarter. New York State Common Retirement Fund now owns 32,247 shares of the biopharmaceutical company’s stock worth $2,818,000 after buying an additional 1,446 shares during the last quarter. Perceptive Advisors LLC lifted its stake in shares of Puma Biotechnology by 26.0% in the third quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock valued at $110,627,000 after buying an additional 190,500 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Puma Biotechnology by 9.6% in the third quarter. Schwab Charles Investment Management Inc. now owns 135,167 shares of the biopharmaceutical company’s stock valued at $16,187,000 after buying an additional 11,787 shares during the period. BlackRock Inc. lifted its stake in shares of Puma Biotechnology by 5.0% in the second quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock valued at $159,973,000 after buying an additional 86,924 shares during the period. Finally, Prudential Financial Inc. bought a new stake in shares of Puma Biotechnology in the second quarter valued at about $302,000. 95.86% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology (PBYI) PT Lowered to $91.00 at JPMorgan Chase & Co.” was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/28/puma-biotechnology-pbyi-pt-lowered-to-91-00-at-jpmorgan-chase-co.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply